https://www.prnewswire.com/news-rel...cell--gene-meeting-on-the-mesa-300930345.html "While optimization of the procedure is continuing, preliminary data show that implanted cells, when effectively engrafted, are capable of producing circulating C-peptide, a biomarker for insulin, in patients with type 1 diabetes. " "The entry criteria of the study require patients to be C-peptide-negative upon enrollment. Previous histological data have shown that, after PEC-01 cells are implanted under the skin and when properly engrafted, they can mature into functional beta cells and other cells of the islet that are responsible for controlling blood glucose levels. Laikind concluded, "ViaCyte has achieved a number of firsts in this field. Now with the first demonstration of insulin production in patients who have received PEC-Direct, we are confident we can be the first to deliver an effective stem cell-derived islet replacement therapy for type 1 diabetes."